Table 2.
Differences in clinical characteristics and genetic information according to rim enhancement in the training set.
| Parameters | Rim enhancement (n = 12) |
No rim enhancement (n = 29) | P value |
|---|---|---|---|
| Clinical characteristics | |||
| Age (years) | 71.0 (64.3–79.3) | 72.0 (66.0–77.5) | 0.767 |
| Male patient | 7 (58.3%) | 16 (55.2%) | 0.853 |
| Body weight (kg) | 71.0 (64.3–67.3) | 60.0 (50.0–70.0) | 0.372 |
| CA 19-9 (U/mL) | 1993.6 (99.9–16911.5) | 261.8 (43.3–1265.9) | 0.176 |
| Tumor size (cm) | 4.8 (4.2–6.0) | 3.3 (2.2–4.9) | 0.021 |
| Clinical stage | |||
| Resectable PDAC | 1 (8.3%) | 9 (31.0%) | 0.221 |
| Borderline resectable PDAC | 1 (8.3%) | 1 (3.4%) | |
| Locally advanced PDAC | 1 (8.3%) | 6 (20.7%) | |
| Metastatic PDAC | 9 (75.0%) | 13 (44.8%) | |
| Mutation profile | |||
| KRAS mutant | 12 (100%) | 25 (86.2%) | 0.235 |
| KRAS VAF (%) | 27.3 (20.8–35.7) | 13.2 (6.3–25.4) | 0.008 |
| TP53 mutant | 9 (75.0%) | 16 (55.2%) | 0.236 |
| TP53 VAF (%) | 13.0 (0–40.1) | 10.5 (0–21.8) | 0.488 |
| CDKN2A mutant | 2 (16.7%) | 4 (13.8%) | 0.813 |
| CDKN2A VAF (%) | 0 (0–0) | 0 (0–0) | 0.956 |
| SMAD4 mutant | 1 (8.3%) | 3 (10.3%) | 0.843 |
| SMAD4 VAF (%) | 0 (0–0) | 0 (0–0) | 0.944 |
Data are presented as median (interquartile range) or number (%).
PDAC, pancreatic ductal adenocarcinoma; CA, Carbohydrate antigen; VAF, variant allele frequency.